Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8254396 | 1.00 | PPARG (0.49) | PPARG | |
| SCHEMBL7860612 | 1.00 | PPARG (0.49) | PPARG | |
| SCHEMBL13292113 | 0.91 | PPARG (0.55) | PPARG | |
| SCHEMBL13813444 | 0.91 | PPARG (0.55) | PPARG | |
| SCHEMBL12798079 | 0.91 | PPARG (0.55) | PPARG | |
| SCHEMBL19394016 | 0.91 | PPARG (0.55) | PPARG | |
| SCHEMBL12798082 | 0.91 | PPARG (0.55) | PPARG | |
| SCHEMBL9680026 | 0.89 | PPARG (0.61) | PPARG | |
| Verbalactone SCHEMBL18529435 | 0.89 | PPARG (0.61) | PPARG | |
| SCHEMBL9681220 | 0.89 | PPARG (0.61) | PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220000854-A1 | DOMPERIDONE ANTINEURODEGENERATIVE COMBINATIONS AND USE | CHASE THERAPEUTICS CORPORATION (US) | 2022-01-06 | — | — | US | disclosed |
| US-20210393595-A1 | ANTI-NEURODEGENERATIVE COMBINATIONS AND USE FOR TREATMENT OF NEURODEGENERATIVE DISEASES | CHASE THERAPEUTICS CORPORATION (US) | 2021-12-23 | — | — | US | disclosed |
| WO-2020139520-A1 | DOMPERIDONE ANTINEURODEGENERATIVE COMBINATIONS AND USE | CHASE THERAPEUTICS CORPORATION (US) | 2020-07-02 | — | — | WO | disclosed |
| US-20200113899-A1 | STATIN COMPOSITIONS AND METHODS FOR USE IN TREATING SYNUCLEINOPATHIES | CHASE THERAPEUTICS CORPORATION (US) | 2020-04-16 | — | — | US | disclosed |
| WO-2019010146-A1 | STATIN COMPOSITIONS AND METHODS FOR USE IN TREATING SYNUCLEINOPATHIES | CHASE THERAPEUTICS CORPORATION (US) | 2019-01-10 | — | — | WO | disclosed |
| EP-3195867-A1 | PYRIMIDINE COMPOUNDS INHIBITING THE FORMATION OF NITRIC OXIDE AND PROSTAGLANDIN E2, METHOD OF PRODUCTION THEREOF AND USE THEREOF | Ustav Organicke Chemie A Biochemie Akademie Ved Cr, v.v.i. (CZ) | 2017-07-26 | — | — | EP | disclosed |
| US-9585964-B2 | Liver targeted conjugates | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-03-07 | — | — | US | disclosed |
| US-8946446-B2 | Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-γ (ROR-γ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases | PHENEX PHARMACEUTICALS AG (DE) | 2015-02-03 | — | — | US | disclosed |
| US-20140142082-A1 | PYRROLO SULFONAMIDE COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (ROR-GAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES | PHENEX PHARMACEUTICALS AG (DE) | 2014-05-22 | — | — | US | disclosed |
| EP-1948600-B1 | LIVER TARGETED CONJUGATES | HARVARD COLLEGE (US) | 2014-04-16 | — | — | EP | disclosed |
| US-20130245101-A1 | Liver Targeted Conjugates | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2013-09-19 | — | — | US | disclosed |
| US-20120101061-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | A.T. Resolve Sarl (CH) | 2012-04-26 | — | — | US | disclosed |
| US-20110245528-A1 | THERAPEUTIC COMPOUNDS | SCHWARTZ C ERIC | 2011-10-06 | — | — | US | disclosed |
| US-20090162316-A1 | LIVER TARGETED CONJUGATES | HARVARD UNIVERSITY (US) | 2009-06-25 | — | — | US | disclosed |
| EP-1969131-A1 | PROCESS FOR THE PREPARATION OF DELTA LACTONES | Isobionics B.V. (NL) | 2008-09-17 | — | — | EP | disclosed |
| US-20080140450-A1 | Treatment of metabolic syndrome with norfluoxetine | AMPLA PHARMACEUTICALS INC. (US) | 2008-06-12 | — | — | US | disclosed |
| US-20070254897-A1 | Compositions and methods for the treatment of cardiovascular disease | RESOLVYX PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| WO-2007068498-A1 | PROCESS FOR THE PREPARATION OF DELTA LACTONES | ISOBIONICS B.V. (NL) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007005941-A2 | LIVER TARGETED CONJUGATES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254897-A1 | Compositions and methods for the treatment of cardiovascular disease | ALOX15B, ALOX5, ALOX15 | PPARG 138/4885 |
| US-20130245101-A1 | Liver Targeted Conjugates | LDLR, HMGCR, FABP1 | PPARG 2355/4885 |
| US-20120101061-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | ALOX15B, ALOX5, ALOX12 | PPARG 111/4885 |
| US-20110245528-A1 | THERAPEUTIC COMPOUNDS | ALOX5, ALOX15B, ALOX12 | PPARG 120/4885 |
| US-20080140450-A1 | Treatment of metabolic syndrome with norfluoxetine | ADRB3, FFAR3, SLC6A4 | PPARG 796/4885 |
| US-20200113899-A1 | STATIN COMPOSITIONS AND METHODS FOR USE IN TREATING SYNUCLEINOPATHIES | SNCA, PARK7, HMGCR | PPARG 974/4885 |
| US-20210393595-A1 | ANTI-NEURODEGENERATIVE COMBINATIONS AND USE FOR TREATMENT OF NEURODEGENERATIVE DISEASES | HTT, PARK7, SNCA | PPARG 2167/4885 |
| US-20220000854-A1 | DOMPERIDONE ANTINEURODEGENERATIVE COMBINATIONS AND USE | PARK7, HTT, TIA1 | PPARG 2031/4885 |
| US-20090162316-A1 | LIVER TARGETED CONJUGATES | HMGCR, FABP1, SLC10A1 | PPARG 2069/4885 |
| US-20140142082-A1 | PYRROLO SULFONAMIDE COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (ROR-GAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES | RORA, RORB, RORC | PPARG 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.